Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.

Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Abstract Text:

J Lee,Y H Im,S H Lee,E Y Cho,Y L Choi,Y H Ko,J H Kim,S J Nam,H J Kim,J S Ahn,Y S Park,H Y Lim,B K Han,J H Yang,J Lee,Y H Im,S H Lee,E Y Cho,Y L Choi,Y H Ko,J H Kim,S J Nam,H J Kim,J S Ahn,Y S Park,H Y Lim,B K Han,J H Yang,

BACKGROUND: The aim of the study was to identify reliable predictive biological markers for treatment outcome following neoadjuvant adriamycin/docetaxel (AT) chemotherapy in locally advanced breast cancer patients. MATERIALS AND METHODS: This study was a phase II study on AT neoadjuvant chemotherapy in locally advanced breast cancer patients. Patients received 50 mg/m(2) of doxorubicin intravenously (IV) over 15 min followed by docetaxel 75 mg/m(2) infused over 1 h, repeated every 3 weeks for three cycles. Surgery was performed within 3-4 weeks following the last cycle of chemotherapy. We analyzed the pre-treatment and post-treatment expression levels of ER, PgR, HER-2, Ki-67 proliferation index, and p53 and examined the correlation between the markers and clinical parameters with treatment response, overall survival and relapse-free survival following neoadjuvant treatment. RESULTS: From July 2001 to September 2004, 61 patients were enrolled. The meaningful parameters adversely influencing survival were post-treatment ER(-) status (P = 0.013) and post-treatment Ki-67 index above 1.0% (P = 0.013). At the multivariate level, the post-treatment Ki-67 proliferation index 1.0%, ER(-) and Ki-67 1.0% with the worst survival (P = 0.033). CONCLUSION: Collectively, post-treatment ER status and Ki-67 proliferation index were prognostic of overall survival following neoadjuvant AT chemotherapy.

Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Publishing Authors By Initials

J Lee,YH Im,SH Lee,EY Cho,YL Choi,YH Ko,JH Kim,SJ Nam,HJ Kim,JS Ahn,YS Park,HY Lim,BK Han,JH Yang,J Lee,YH Im,SH Lee,EY Cho,YL Choi,YH Ko,JH Kim,SJ Nam,HJ Kim,JS Ahn,YS Park,HY Lim,BK Han,JH Yang,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cancer chemotherapy and pharmacology

VOLUME: 61

Page Numbers: 569-77

Journal Abbreviation: Cancer Chemother. Pharmacol.

ISSN: 0344-5704

DAY: 17

MONTH: 05

YEAR: 2007

Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7806519

Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.

AFFILIATION: Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-dong, Kangnam-gu, Seoul, 135-710, South Korea, imyh@smc.samsung.co.kr.

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer Chemother Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer Related Publications

• Application of mucin quantitative competitive reverse transcription polymerase chain reaction in assisting the diagnosis of malignant pleural effusion.
• Aquaporin gene delivery to kidney.
• Effects of vitamin E and selenium supplementation on esophageal adenocarcinogenesis in a surgical model with rats.
• Late postoperative complication of the foldable lens implantation: opacification of the intraocular lenses.
• Regulation of the Cool/Pix proteins: key binding partners of the Cdc42/Rac targets, the p21-activated kinases.
• Tissue array technique for p53 expression in human ovarian neoplasms.
• [A case of cerebral schistosomiasis misdiagnosed as brain tumor]
• [Chromosome t (8; 21) and t (15; 17) in a patient with acute myeloid leukemia]
• [Construction of a subtracted cDNA library of differentially expressed genes in human normal liver tissue and primary hepatocellular carcinoma tissue]
• [Control genes of chondrocyte apoptosis in osteoarthritic articular cartilage]
• [Effects of cactus, alove veral, momorcica charantia on reducing the blood glucose of diabetic mice]
• [Force-dependent effects of interleukin-8 gene expression in endothelial cells exposed on fluid shear stress]
• [Human cytomegalovirus inhibits the proliferation of CFU-MK in vitro]
• [Immunorelated pancytopenia]
• [Intro-extro cranial approach treat serious post fronto-orbital fracture deformities]
• [Oxaliplatin in combination with LV5FU2 for advanced/metastatic gastric cancer-a multicenter study]
• [Patients of severe acute respiratory syndrome with hypoxemia treated by anisodamine]
• [Polylactic acid combined with recombinant human bone morphogenetic protein and basic fibroblast growth factor to repair the mandibular defects in rabbits]
• [Protection on proliferation of intestinal epithelial cells against hypoxia-reoxygenation through recombinant heat shock protein 70 adenovirus transfection]
• [Relationship between the changes of beta2-microglobulin in blood and urine and kidney involvements in children with pneumonia]
• [Research progress on the signal transduction and the molecular regulation of oocyte meiotic maturation]
• [Schistosomiasis investigation at 4 villages of Yangjiayuan during a flood in 1999]
• [Second-line Hycamtin in the treatment of lung cancer]
• [Sequential intensified immunosuppressive therapy combining with hematopoietic growth factors in the treatment of severe aplastic anemia]
• [Seventy degrees lateral decubital intraperiteanal laparoscopic adrenal surgery]
• [Studies on photochemical disinfectant enamelled-ware of toxicity experiments]
• [Study on the transformation from myelodysplastic syndromes into acute leukemias]
• [Surgical management of sacrococcygeal chordomas]
• [The genetic characteristic of HLA-DRB1 locus in the Jiangsu-Zhejiang-Shanghai Han population and a comparison of its frequency distribution with that of other populations]
• [The postburn changes in gastric mucosal blood flow and Na+-K+-ATPase activity and their effects on gastric transmucosal potential difference in severely scalded rats]